vs
Side-by-side financial comparison of Mirum Pharmaceuticals, Inc. (MIRM) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Mirum Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($148.9M vs $129.7M, roughly 1.1× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 49.8%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 46.7%).
Mirum Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare, debilitating liver diseases that have high unmet medical needs, serving both pediatric and adult patient groups across North America, Europe and other global regions.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
MIRM vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.9M | $129.7M |
| Net Profit | $-5.7M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | -3.1% | -25.0% |
| Net Margin | -3.8% | — |
| Revenue YoY | 49.8% | 73.4% |
| Net Profit YoY | 75.9% | — |
| EPS (diluted) | $-0.10 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.9M | $129.7M | ||
| Q3 25 | $133.0M | $164.9M | ||
| Q2 25 | $127.8M | $114.4M | ||
| Q1 25 | $111.6M | $81.7M | ||
| Q4 24 | $99.4M | $74.8M | ||
| Q3 24 | $90.4M | $62.9M | ||
| Q2 24 | $77.9M | $54.1M | ||
| Q1 24 | $69.2M | $41.4M |
| Q4 25 | $-5.7M | — | ||
| Q3 25 | $2.9M | $25.7M | ||
| Q2 25 | $-5.9M | $-12.8M | ||
| Q1 25 | $-14.7M | $-41.2M | ||
| Q4 24 | $-23.8M | — | ||
| Q3 24 | $-14.2M | $-54.8M | ||
| Q2 24 | $-24.6M | $-70.4M | ||
| Q1 24 | $-25.3M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | -3.1% | -25.0% | ||
| Q3 25 | 2.0% | 15.1% | ||
| Q2 25 | -3.9% | -11.1% | ||
| Q1 25 | -13.6% | -52.2% | ||
| Q4 24 | -24.4% | -81.2% | ||
| Q3 24 | -14.0% | -89.3% | ||
| Q2 24 | -31.1% | -125.1% | ||
| Q1 24 | -38.2% | -336.5% |
| Q4 25 | -3.8% | — | ||
| Q3 25 | 2.2% | 15.6% | ||
| Q2 25 | -4.6% | -11.1% | ||
| Q1 25 | -13.2% | -50.4% | ||
| Q4 24 | -23.9% | — | ||
| Q3 24 | -15.8% | -87.1% | ||
| Q2 24 | -31.6% | -130.1% | ||
| Q1 24 | -36.5% | -328.9% |
| Q4 25 | $-0.10 | $0.04 | ||
| Q3 25 | $0.05 | $0.28 | ||
| Q2 25 | $-0.12 | $-0.14 | ||
| Q1 25 | $-0.30 | $-0.47 | ||
| Q4 24 | $-0.49 | $-0.71 | ||
| Q3 24 | $-0.30 | $-0.70 | ||
| Q2 24 | $-0.52 | $-0.91 | ||
| Q1 24 | $-0.54 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $383.3M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $314.7M | $114.8M |
| Total Assets | $842.8M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $383.3M | $93.0M | ||
| Q3 25 | $375.5M | $110.9M | ||
| Q2 25 | $304.6M | $75.2M | ||
| Q1 25 | $277.7M | $61.9M | ||
| Q4 24 | $280.3M | $58.5M | ||
| Q3 24 | $284.4M | $36.4M | ||
| Q2 24 | $278.4M | $32.3M | ||
| Q1 24 | $302.8M | $43.3M |
| Q4 25 | $314.7M | $114.8M | ||
| Q3 25 | $292.0M | $73.6M | ||
| Q2 25 | $255.2M | $32.7M | ||
| Q1 25 | $233.3M | $32.8M | ||
| Q4 24 | $225.6M | $59.1M | ||
| Q3 24 | $232.0M | $-30.5M | ||
| Q2 24 | $229.0M | $15.1M | ||
| Q1 24 | $234.6M | $74.1M |
| Q4 25 | $842.8M | $605.2M | ||
| Q3 25 | $785.1M | $538.6M | ||
| Q2 25 | $725.8M | $555.3M | ||
| Q1 25 | $690.2M | $548.8M | ||
| Q4 24 | $670.8M | $594.1M | ||
| Q3 24 | $667.9M | $504.4M | ||
| Q2 24 | $660.8M | $551.1M | ||
| Q1 24 | $652.0M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.1M | $60.7M |
| Free Cash FlowOCF − Capex | $5.5M | — |
| FCF MarginFCF / Revenue | 3.7% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $54.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.1M | $60.7M | ||
| Q3 25 | $39.7M | $14.3M | ||
| Q2 25 | $12.0M | $5.0M | ||
| Q1 25 | $-2.0M | $-42.2M | ||
| Q4 24 | $-5.1M | $-35.7M | ||
| Q3 24 | $4.0M | $-42.5M | ||
| Q2 24 | $-3.8M | $-40.2M | ||
| Q1 24 | $15.2M | $-119.0M |
| Q4 25 | $5.5M | — | ||
| Q3 25 | $39.5M | $14.2M | ||
| Q2 25 | $11.9M | — | ||
| Q1 25 | $-2.0M | — | ||
| Q4 24 | $-5.1M | — | ||
| Q3 24 | $3.8M | — | ||
| Q2 24 | $-4.6M | $-40.3M | ||
| Q1 24 | $15.2M | — |
| Q4 25 | 3.7% | — | ||
| Q3 25 | 29.7% | 8.6% | ||
| Q2 25 | 9.3% | — | ||
| Q1 25 | -1.8% | — | ||
| Q4 24 | -5.1% | — | ||
| Q3 24 | 4.2% | — | ||
| Q2 24 | -5.9% | -74.5% | ||
| Q1 24 | 22.0% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.1% | 0.1% | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 1.0% | 0.2% | ||
| Q1 24 | 0.0% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 13.66× | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MIRM
| Livmarli | $106.4M | 71% |
| Bile Acid Medicines | $42.5M | 29% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
